Johnson & Johnson (JNJ) Stock Climbs Following Strong Q1 2026 Performance

Key Highlights

• Johnson & Johnson delivered Q1 adjusted earnings of $2.70 per share, surpassing the Street’s $2.68 projection, while revenue reached $24.1 billion versus expectations of $23.6 billion.
• The pharmaceutical segment climbed 11.2% from last year to $15.4 billion, with Darzalex generating $4.0B and Tremfya contributing $1.6B.
• Management increased 2026 annual sales projections to $100.8 billion and lifted adjusted earnings per share forecast to $11.55.
• Newly approved psoriasis treatment Icotyde is projected to achieve approximately $10 billion in peak annual revenue, according to Truist Securities analysis.
• Shares of JNJ have climbed 15% this year through 2026, significantly outpacing the S&P 500’s 0.6-1% advance.

The healthcare conglomerate unveiled its first-quarter 2026 financial performance Tuesday morning, delivering figures that exceeded analyst projections on both the top and bottom lines.

Revenue for the period totaled $24.1 billion, representing a 10% increase versus the prior-year quarter and topping the Wall Street consensus of $23.6 billion compiled by FactSet. On an adjusted basis, earnings per share reached $2.70, narrowly beating the $2.68 forecast.

Shares responded positively, climbing approximately 1.2% during premarket hours after the announcement.

Johnson & Johnson, JNJ

The results mark another chapter in J&J’s ongoing transformation. The company has deliberately pivoted away from its consumer health business in recent years — having divested the Kenvue division, currently in the process of being acquired by Kimberly-Clark — to sharpen its focus on pharmaceuticals and medical technology.

The pharmaceutical business delivered standout performance, expanding 11.2% compared to last year to reach $15.4 billion. This figure exceeded FactSet’s projection of $15.2 billion.

Darzalex, the company’s leading treatment for multiple myeloma, generated $4.0 billion during the quarter, a substantial increase from $3.2 billion in the year-ago period. Analysts had anticipated $3.9 billion.

Tremfya, an IL-23 inhibitor prescribed for autoimmune disorders, recorded $1.6 billion in quarterly revenue, jumping from $956 million last year and comfortably surpassing the $1.4 billion consensus.

Autoimmune Treatment Advances

Regulatory approval for Tremfya’s subcutaneous formulation arrived last September for treating ulcerative colitis and Crohn’s disease, establishing it as the first medication in its class enabling patient self-administration at home. This feature provides a competitive edge over AbbVie’s Skyrizi, which necessitates clinic-based initial infusions.

Additionally, J&J secured FDA clearance last month for Icotyde, an oral IL-23 inhibitor tablet for plaque psoriasis, stemming from a 2017 licensing agreement with Protagonist Therapeutics. Truist Securities analyst Srikripa Devarakonda projects Icotyde could eventually achieve peak revenues approaching $10 billion. The company hasn’t yet reported any commercial sales data.

The medical devices segment generated $8.6 billion in revenue, matching analyst expectations.

Net profit totaled $5.2 billion, falling short of the FactSet consensus of $6.5 billion — marking the second straight quarter where bottom-line earnings disappointed versus projections.

Updated Outlook and Ongoing Litigation

Looking ahead to the full year, management now anticipates revenue of $100.8 billion, revised upward from the previous $100.5 billion estimate. The adjusted earnings per share forecast was similarly elevated to $11.55 from $11.03. Wall Street had been modeling $11.54 per share on sales of $100.6 billion.

The corporation continues to navigate significant legal challenges. As of the fourth quarter 2025, J&J was defending against 74,360 lawsuits alleging it knowingly marketed talcum powder products containing asbestos, a known carcinogen. Its latest effort to settle these claims through a bankruptcy mechanism involving subsidiary Red River Talc was rejected by a Texas court, allowing individual cases to move forward.

J&J continues to assert that its baby powder product, now marketed under the Kenvue brand, contains no asbestos and is completely safe.

Among the 29 analyst firms monitoring the stock through FactSet, 17 maintain Buy-equivalent ratings. Two have assigned Sell recommendations.

JNJ stock has advanced 15% year-to-date in 2026, substantially outperforming the S&P 500’s gain of roughly 0.6% to 1% during the same timeframe.

The post Johnson & Johnson (JNJ) Stock Climbs Following Strong Q1 2026 Performance appeared first on Blockonomi.